Cardiovascular system

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Genuity Science Wins 2021 BIG Innovation Award for Novel Genome Sequencing Approach

Tuesday, January 12, 2021 - 7:11pm

BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.

Key Points: 
  • BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.
  • The BIG innovation Awards recognize those organizations and people who bring new ideas to life, and change the way we experience the world.
  • Genuity Science's AI technology sifted through a large amount of high-dimensional data without a starting hypothesis, allowing the teams to uncover novel causal connections at the single-cell level.
  • "We are honored to be recognized for our deep learning approach that helped, in part, discover the underlying cause of thoracic aortic aneurysms," said Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science.

Endospan Enrolls First Patient in the TRIOMPHE IDE Study

Tuesday, January 12, 2021 - 2:00pm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.
  • The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS in treating thoracic aortic lesions involving the aortic arch.
  • With the first patient enrolled in the TRIOMPHE IDE study, Endospan marks the next crucial milestone towards US approval for the NEXUS Aortic Arch Repair Stent Graft System, said Kevin Mayberry, CEO.
  • The NEXUS is specifically engineered for total endovascular arch repair to address the specific challenges of the aortic arch anatomy.

Patent Foramen Ovale (PFO) Closure Devices Market Insights, Competitive Landscape and Market Forecast Report 2017-2025 - ResearchAndMarkets.com

Thursday, January 7, 2021 - 2:46pm

The "Patent Foramen Ovale (PFO) Closure Devices - Market Insights, Competitive Landscape and Market Forecast - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Patent Foramen Ovale (PFO) Closure Devices - Market Insights, Competitive Landscape and Market Forecast - 2025" report has been added to ResearchAndMarkets.com's offering.
  • This 'Patent Foramen Ovale (PFO) Closure Devices-Market Insights, Competitive Landscape and Market Forecast-2025' report delivers an in-depth understanding of the patent foramen ovale closure devices, historical and forecasted number of patients eligible for PFO closure as well as the patent foramen ovale closure devices market trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • Patent Foramen Ovale Closure Devices: Market Drivers and Barriers
    The report provides insights into the market driving factors that has affected the Patent Foramen Ovale Closure Devices Market such as prevalence of PFO, escalating preferences for minimally-invasive procedures, procedure performed is simple, safer, technically-feasible and effective, less-time consuming.
  • The report helps in developing business strategies by understanding trends shaping and driving the global Patent Foramen Ovale closure devices market.

Ultromics receives FDA Clearance for a first-of-kind solution in Echocardiography to help clinicians diagnose disease

Wednesday, January 6, 2021 - 11:00am

Misdiagnosis happens with one in five patients potentially resulting in poor treatment and outcomes, which is compounded by the subjectivity of interpretation between clinicians.

Key Points: 
  • Misdiagnosis happens with one in five patients potentially resulting in poor treatment and outcomes, which is compounded by the subjectivity of interpretation between clinicians.
  • Dr Ross Upton, founder and CEO of Ultromics ,comments: "Coronary artery disease is a huge global burden, affecting tens of millions of peoples' lives worldwide.
  • Ultromics will offer EchoGo Pro as a Stress-Echo module in the EchoGo suite alongside EchoGo Core , its AI solution for automated Systolic function and Strain analysis.
  • Ultromics is a global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions - empowering clinicians to make fast, accurate decisions when diagnosing cardiovascular disease.

VOLTA MEDICAL raises 23 million Euros to revolutionize persistent AF ablation

Tuesday, January 5, 2021 - 2:00pm

MARSEILLE, France, Jan. 5, 2021 /PRNewswire/ -- Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 23 million Euros.

Key Points: 
  • MARSEILLE, France, Jan. 5, 2021 /PRNewswire/ -- Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 23 million Euros.
  • After developing the first commercially available AI software to help electrophysiologists improve management of cardiac arrythmias, Volta Medical is now preparing to transform the way ablation procedures will take place in the future.
  • Theophile Mohr-Durdez, CEO and co-founder of Volta Medical mentioned: "We are excited to be able to complete our highly ambitious medical program with the start of TAILORED-AF, a new randomized controlled trial (RCT).
  • Among these disturbances, atrial fibrillation (AF) is the most common[1] and currently affects over 30 million patients worldwide.

Asia-Pacific Interventional Cardiology Market Outlook to 2025, with Focus on Cardiac Catheters, Coronary Guidewires, Coronary Stents and More - ResearchAndMarkets.com

Monday, January 4, 2021 - 4:19pm

The "Asia-Pacific Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's

Key Points: 
  • The "Asia-Pacific Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's
    This is a comprehensive databook report, covering key market data on the Asia - Pacific Interventional Cardiology market.
  • The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Cardiac Catheters, Coronary Guidewires, Coronary Stents, Intravascular Ultrasound Systems (IVUS) and PTCA Balloon Catheters.
  • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the Asia - Pacific Interventional Cardiology Market.

Worldwide Industry for Isosorbide to 2025 - by Product, Application, End-use and Region

Monday, December 21, 2020 - 7:15pm

The derivatives of isosorbide, namely isosorbide dinitrate and isosorbide mononitrate, find extensive applications across various end use industries across the globe.

Key Points: 
  • The derivatives of isosorbide, namely isosorbide dinitrate and isosorbide mononitrate, find extensive applications across various end use industries across the globe.
  • Amongst these, isosorbide dinitrate is a solid, colorless crystal that is widely used as a vasodilator agent in the treatment of angina pectoris.
  • Apart from this, manufacturers operating in the industry are adopting waste recycling strategies for minimizing waste emission during the production of isosorbide.
  • What is the structure of the global isosorbide market and who are the key players?

Global Cardiovascular Devices Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Monday, December 21, 2020 - 11:00am

There has been an increase in the incidence of cardiovascular diseases (CVD), wherein a long-term ECG monitoring is necessary.

Key Points: 
  • There has been an increase in the incidence of cardiovascular diseases (CVD), wherein a long-term ECG monitoring is necessary.
  • Moreover, with the introduction of wireless ECG, doctors can monitor and diagnose the patient remotely on time, which further fuels market growth.
  • Furthermore, increasing cardiovascular diseases, such as arrhythmias, stroke, and high blood pressure, are increasing the demand for cardiovascular devices, along with rising awareness and demand for minimally invasive surgeries, which, in turn, are expected to drive the cardiovascular devices market.
  • Furthermore, the ongoing development in the cardiovascular field and technological advancements are expected to propel the growth of the US cardiovascular devices market.